Aims: Clear cell meningioma (CCM) is a rare subtype of meningioma and shows not only unusual histology, but also unique clinical features. Recently, SMARCE1 mutations have been shown to cause spinal and cranial CCMs. We present 12 cases which were diagnosed with CCM in a single institution between 1997 and 2014, and investigate their SMARCE1 mutation status. Methods and results: To investigate the SMARCE1 mutation status of these tumours, we used a combination of Sanger sequencing and multiplex ligationdependent probe amplification analysis and also performed SMARCE1 immunohistochemical staining. We found both SMARCE1 mutational hits, including novel SMARCE1 mutations, in six of eight tested patients. Immunohistochemical analysis showed loss of SMARCE1 protein staining in all but two cases. Two individuals who were diagnosed originally with CCM were negative for SMARCE1 mutations, but tested positive for NF2 mutations. As a result, these two tumours were re-analysed and eventually reclassified, as a microcystic and a mixed pattern of meningothelial meningioma with focal clear cell areas, respectively. Conclusions: These results expand the spectrum of pathogenic variants in SMARCE1 and show that mutation screening can help to facilitate meningioma classification. This may have implications for prognosis and future clinical management of patients, as CCMs are classed as grade II tumours, while microcystic and meningothelial meningiomas are classed as grade I.
Introduction
Meningiomas are the most common form of primary neoplasm in the adult central nervous system (CNS). 1, 2 Meningiomas account for 1.0-4.6% of childhood brain tumours. 3 While most meningiomas have a good prognosis, high recurrence rates have been observed for World Health Organization (WHO) grades II and III meningiomas. 4 Among grades II and III meningiomas, clear cell meningioma (CCM) is rare, consisting of only 0.2-0.81% of all meningiomas. 5 Histologically, CCMs are characterized by patternless distribution of polygonal cells with a clear, glycogen-rich cytoplasm and blocky, perivascular and interstitial collagen. CCMs show not only unusual histology, but also unique clinical features. They tend to occur in young patients, and are more likely to recur or metastasize than other common subtypes. 6 Recurrence and CNS metastasis occurred in 37. 8 and 8 .1% of the cases reported in the literature, respectively. 6 Although the molecular genetic alterations occurring in meningiomas have not yet been elucidated fully, 5, 7 meningiomas exhibit a wide spectrum of molecular alterations. NF2 mutations are the most common somatic genetic alteration found in sporadic meningiomas, and germline mutation of the NF2 gene is known to predispose to multiple meningiomas as part of the neurofibromatosis type 2 (NF2) phenotype. 8 Genomic sequencing of a subset of meningiomas lacking NF2 alteration elucidated recurrent SMO and AKT1 mutations, which have the potential to guide new therapeutic strategies. 9 Furthermore, genomic changes are associated with histological subtype and genomic data of various subtypes are expected to facilitate more accurate histological grading and subtyping. [10] [11] [12] [13] In case of CCM, germline loss-of-function mutations in the SMARCE1 chromatin remodelling factor were identified as a cause of both spinal and cranial CCM. 8, 14 To date, 12 families with SMARCE1-associated CCM have been reported (Table 1 ).
14-18 15 mutations appear to be specific for the clear cell histological subtype, rather than tumour location or syndromic presentation. 8 Previously, intracranial CCM has also been reported in one child diagnosed with NF2 disease on clinical grounds 19 and one adult, also on clinical grounds, 16 while most meningiomas that occur in NF2 show a fibroblastic or transitional histology. 20 In this study, we report 12 cases which were diagnosed as a CCM in a single institute in Korea during an 18-year period. We investigated the involvement of SMARCE1 mutation in these tumours.
SMARCE1

Materials and methods
A retrospective search of the pathology database at the Samsung Medical Center, using the term 'CCM', identified a total of 14 samples from 12 patients. All patients underwent surgery at the neurosurgery unit of the Samsung Medical Center, Seoul, South Korea, between 1997 and 2014. For patient 5, who underwent a two-staged operation, two surgical specimens (5-1 and 5-2) were included. Patient 6 underwent an initial operation at an outside hospital. The sample used in this study was a recurrent tumour with a 9-year interval. The primary tumour sample for this patient was not available. For patient 11, who showed progression of disease, the initial tumour (11-1) and progressed tumour , with a 3-month interval, were analysed. A blood sample was also acquired from this patient. All patients were followed-up until October 2015, with a median follow-up time of 59 months. Formalin-fixed paraffin-embedded (FFPE) tissue was obtained from a retrospectively collected archive. Clinical information including age, tumour site, local and adjuvant therapy, recurrence and survival data were evaluated by reviewing the medical records. The study was approved by the institutional review board (IRB) at the Samsung Medical Center.
D N A E X T R A C T I O N
Genomic DNA was extracted using a Qiagen DNA FFPE tissue kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. After extraction, concentration, 260/280 and 260/230 nm ratio were measured by spectrophotometer (ND1000; Nanodrop Technologies, Thermo-Fisher Scientific, Waltham, MA, USA).
S A N G E R S E Q U E N C I N G
SMARCE1 exons were amplified from tumour DNA, using GoTaq G2 Green Master Mix (Promega, Southampton, UK). The products were purified using AxyPrep Mag polymerase chain reaction (PCR) cleanup beads (Appleton Woods, Birmingham, UK). Sequencing PCR was performed using the BigDye â Terminator version 3.1 Cycle Sequencing Kit (ABI; Life Technologies, Paisley, UK). The products were purified using AxyPrep Mag DyeClean beads (Appleton Woods) and analysed on an ABI 3730xl DNA Analyzer (ABI; Life Technologies).
MLPA was carried out using SALSA MLPA kits, X072-X1 and P043-NF2 (MRC-Holland, Amsterdam, the Netherlands), according to the manufacturer's instructions. Briefly, 100 ng DNA were used for hybridization, ligation and amplification of exon probes for control and test samples and the products were analysed on an ABI 3100 sequencer (Applied Biosystems, Warrington, UK).
I M M U N O H I S T O C H E M I S T R Y
Paraffin-embedded meningioma sections were immunostained for SMARCE1 protein, as described previously.
14 Briefly, 1:100 anti-SMARCE1 HPA003916 antibody (Sigma-Aldrich, St Louis, MO, USA) was used to stain sections, using an indirect peroxidase method on the Roche Ultra IHC autostainer. This antibody is polyclonal and has been raised against the C-terminal end of SMARCE1 (amino acids 301-408).
Results
C L I N I C O P A T H O L O G I C A L F E A T U R E S O F 1 2 P A T I E N T S D I A G N O S E D W I T H C C M
The clinicopathological information of the patients is summarized in Table 2 . There were five spinal tumours and seven cranial tumours. The tumour sites were as follows: spinal cord, frontal lobe, cerebellomedullary cistern, cerebellopontine angle, and falx cerebelli and low cranial nerve. The sample from patient 6 was a recurrent tumour (9-year interval) and patient 11 showed disease progression (3-month interval). However, to date, none of the patients have died due to tumour recurrence or progression. All patients reported no familial history or past history of brain or spinal tumour.
S M A R C E 1 S T A T U S
Immunohistochemical analysis of paraffin-embedded tissue from each tumour showed loss of SMARCE1 protein staining in 12 of 14 tumours (Figure 1 , Table 2 ).
To investigate the SMARCE1 mutation status of these tumours, we used a combination of Sanger sequencing and MLPA analysis ( Table 2 ). Four tumours were excluded from genetic analysis due to poor DNA quality. We found two SMARCE1 mutational hits in each of six out of eight tested patients. We identified two splice-site mutations, three nonsense mutations, three frameshift mutations and one indel. 14 In the current study this mutation was associated with a recurrent tumour.
For patient 11, showing tumour progression, an identical mutation, c.331G>T, p.(E111*), was found in both the original and progressed tumour samples (11-1 and 11-2). A blood sample was available for analysis and we were able to confirm the presence of this mutation in the germline. Two surgical specimens for the tumour from patient 5 (5-1 and 5-2) also showed identical mutations.
Tumours from three individuals contained two point mutations, rather than one point mutation and loss of heterozygosity (LOH). These included an exon 6 splice-site mutation and an exon 10 frameshift in the cranial CCM of a 16-year-old male; two frameshift mutations involving exons 3 and 8 were identified in the spinal CCM of a 19-year-old female. Finally, a nonsense mutation in exon 6 and a frameshift alteration in exon 10 were detected in the spinal CCM of a 10-year-old female.
For the two tumours in which no SMARCE1 mutations were found (from patients 8 and 9), we analysed the NF2 gene and identified bi-allelic inactivating mutations in both tumours. The first contained a frameshift mutation, c.579delA, p.(Ala194Alafs*15) in exon 6, with LOH. The second tumour contained the missense mutation, c.755C>T, p.(Pro252Leu), in exon 8, also with LOH. The variant p.(Pro252Leu) is non-truncating, but was not found on ESP6500SI-V2 or ExAC and was predicted to be damaging by Polyhphen2, SIFT, Mutation Taster and Align GVGD, suggesting that it is pathogenic.
H I S T O L O G I C A L R E C L A S S I F I C A T I O N
As we identified two NF2 alterations in each of these last two tumours, SMARCE1 protein staining was positive, and as we could not find SMARCE1 mutations in either of these tumours, the tissue was reassessed (by SA, YS and DdP). It was determined that the major histology for the tumour from patient 8 was, in fact, microcystic (Figure 2 ). For patient 9, the tumour contained a focal clear cell component; however, the tumour was heterogeneous in composition, also containing meningothelial and small cell constituents ( Figure 2 ).
After removing these two males without conventional CCM morphology, the male-to-female ratio was 6:4 and cranial-to-spinal tumour ratio was equal (5:5) . In this cohort, the mean and median ages at diagnosis of meningioma were not significantly different between males (27 and 24 years, respectively) and females (23 and 24.5 years, respectively).
Discussion
Meningiomas consist of various histological subtypes which appear to be determined by distinct genetic alterations. Recently, several large-scale genomic studies of meningioma extended our knowledge of somatic molecular alteration in various types of meningioma. 9, 10, 13, 21, 22 These data can be used to fine-tune diagnostic accuracy, both subtyping and potentially grading. [11] [12] [13] 21 In CCM, germline loss-of-function mutations in the SMARCE1 chromatin remodelling factor were identified as a cause of both spinal and cranial CCM. 14, 16 To date, including the current study, pathogenic SMARCE1 mutations have been associated with CCM in individuals from 20 separate families. The majority of identified SMARCE1 mutations are nonsense or frameshift variants, predicted to lead to protein inactivation and complete loss of the protein product. Previous studies have shown two unrelated families to have a large multi-exon deletion, while one family has an intra-exonic inversion mutation and two families have a small exonic indel (Table 1) . To date, missense mutations have not been associated with CCM. The majority of SMARCE1 nonsense and frameshift mutations have been found in exon 6. The functional significance of this region is highlighted further by three splice-site mutations that have been found in exons 5 and 6, with the potential to generate aberrantly spliced transcripts and therefore to perturb protein structure and function. However, immunohistochemical analysis of available tissue has shown loss of SMARCE1 protein in all SMARCE1 mutation-positive tumours, suggesting that if any alternatively spliced products are generated, they are unstable.
Mutational analysis in the current cohort identified two SMARCE1 mutations in eight tumours from six people. No SMARCE1 mutations were identified in two remaining tumours, but two mutational hits were identified in NF2 (a point mutation and LOH) in each tumour. Each of these NF2-mutated tumours showed an unconventional morphology for CCM, and subsequent re-analysis of their histology established one to be a microcystic meningioma (patient 8) and the other to have a mixed histology (patient 9). Microcystic meningiomas are known to be problematic to distinguish from CCMs. The tumour from patient 9 contained a focal clear cell component; however, the tumour was heterogeneous in composition, also containing meningothelial and small cell constituents (Figure 2) .
CCMs are classed as grade II meningiomas and show unique clinical features. They tend to occur in young patients, and are more likely to recur or metastasize than other common subtypes. 6 In this cohort the mean and median ages at diagnosis of meningioma were not significantly different between males (27 and 24 years, respectively) and females (23 and 24.5 years, respectively). This is in contrast to previous studies, indicating an earlier onset in males versus females. The reason for this is unknown. However, as the mutation status in tumours from four adult males is unknown and no lymphocyte DNA was available for any of these patients to test germline status, it is possible that these are sporadic tumours occurring at a later age, while the younger male patients have a germline predisposition. The limitations of this study are that the followup period was relatively short for some patients and germline DNA was only available for one patient, limiting our ability to determine which cases were due to germline mutation and which were sporadic. This study adds to the known spectrum of meningioma-associated variants in SMARCE1 and the natural history of CCMs. To our knowledge, this is the first study examining SMARCE1 mutation status in Asian patients with CCM. It also demonstrates the utility of genetic screening in accurate classification of meningiomas. This may have implications for future clinical management of patients, as CCMs are classed as grade II tumours, while microcystic are classed as grade I. The study findings also raise the prospect that meningiomas with focal clear cell components do not share the same genotype as conventional, 'pure' CCM and may not, by implication, carry the same adverse prognosis. This, however, requires validation, requiring the genotyping of larger numbers of mixed meningiomas with focal clear cell areas.
